Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline
Cet article présente les recommandations de trois sociétés savantes américaines (American Society for Radiation Oncology, American Society of Clinical Oncology et American Urological Association) sur l'utilisation de la radiothérapie hypofractionnée pour traiter un cancer de la prostate de stade localisé
External beam radiation therapy (EBRT) is a standard definitive treatment option for men with localized prostate cancer and confers long-term prostate cancer control outcomes equivalent to radical prostatectomy.1 Improvements in imaging and computing over the past two decades have led to a number of technical advances in planning and delivery of prostate EBRT. Notably, these include the use of cross-sectional imaging for treatment planning2 and innovations in treatment delivery, including intensity modulation3 and daily image guidance.4 These technical advances have permitted more precise and conformal delivery of escalated doses of radiation to the prostate, thereby improving the therapeutic ratio.
Journal of Clinical Oncology , article en libre accès, 2017